[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@zhaoweiasu Wei Zhao
Wei Zhao posts on X about $beam, $regn, $150m, $prme the most. They currently have XXXXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours.
Engagements: XXX #
- X Week XXXXXX +27%
- X Month XXXXXX -XX%
- X Months XXXXXXX +83%
- X Year XXXXXXX +29%
Mentions: XX #
- X Week X -XX%
- X Month XX no change
- X Months XXX +8.60%
- X Year XXX +18%
Followers: XXXXX #
- X Week XXXXX +0.83%
- X Month XXXXX +1.80%
- X Months XXXXX +21%
- X Year XXXXX +40%
CreatorRank: XXXXXXXXX #
Social Influence
Social category influence cryptocurrencies stocks
Social topic influence $beam #16, $regn #23, $150m #48, $prme #15, what is, at least, $crsp, ind, ceo, wilson
Top assets mentioned BEAM (BEAM) Regeneron Pharmaceuticals Inc (REGN) CRISPR Therapeutics AG (CRSP) Kymera Therapeutics, Inc. Common Stock (KYMR)
Top Social Posts
Top posts by engagements in the last XX hours
"Risto-cel (BEAM-101) ASH 2025 (08/06/25 data cut-off) No VOCs so far vs. 1015% in Casgevy Patient XX had XX VOCs in the X years before treatment and is now VOC-free $BEAM"
X Link 2025-12-06T16:38Z 6835 followers, 5703 engagements
"$REGN paid Tessera $150M for what is essentially a knock-off prime-editing AATD program. 🔴And lets be honest: $150M isnt validation it makes Tessera look desperate and Regenerons move looks like a puzzling gamble. 🤔Its hard to imagine a reputable CRISPR company selling XX% of its flagship program for a sum this small right before human data 🚩To investors that looks like low conviction that the asset can beat BEAMs or Prime Medicines AATD programs on top of the very obvious IP/FTO overhang"
X Link 2025-12-01T19:27Z 6836 followers, 6456 engagements
"If Tessera believes it is superior to BEAM-302 it should wait until dosing the 1st patient. It is also at least XX months behind BEAM-302. For $REGN they have little to lose beyond the $150M making it a calculated gamble for them. Best case they pay $PRME a large sum; worst case they face an injunction"
X Link 2025-12-01T19:58Z 6835 followers, XXX engagements
"Both the program and the technology are patented. I don't think there is any gray area here. For instance if a company wants to use base or prime editing it will need a license from BEAM or PRME for commercialization. NTLA uses Cas9 which creates indels and provokes dangerous immune responses. The field needs to move away from risky DSB cutting"
X Link 2025-12-02T02:42Z 6836 followers, XXX engagements
"Besides confirming that both $CRSP and Tessera copied prime editing for AATD the $PRME CEO also emphasized the companys confidence/hope that their liver-directed LNP could offer a wider therapeutic window than competitors pending clinical confirmation. Importantly a single IND can include multiple mutations for the same disease. For example a Wilson Disease IND would include both H1069Q and R778L"
X Link 2025-12-02T18:47Z 6836 followers, 5105 engagements
"Risto-cel (BEAM-101) vs Casgevy âž¡Mean Hb: XXXX (using n=17 month X data 1g/dL higher than normal) vs XXXX (1g/dL lower than normal) âž¡HbF %: XX% vs XX% âž¡Normal Hb Range Adult men: 13.517.5 g/dL Adult women (non-pregnant): 12.015.5 g/dL $BEAM"
X Link 2025-12-06T17:15Z 6836 followers, 1799 engagements
"$KYMR AD Mean % Change in EASI âž¡ KT-621 (100/200 mg QD) Day XX Ph1b (n=22): XX% âž¡ Dupilumab (300 mg Q2W) Day XX Ph3 (n=457): XX% âš KT-621s Ph1b study had no placebo control and a much smaller n so its results should be treated cautiously. Still KT-621s trajectory shows no sign of plateau by week X suggesting it could outperform dupilumab if the trend is confirmed in larger controlled trialsnot just an oral dupi but an oral dupi+"
X Link 2025-12-09T07:44Z 6836 followers, 6450 engagements
"@avidresearch Cure Not even close. Besides it has long term safety issues"
X Link 2025-12-10T15:22Z 6835 followers, XXX engagements
"@avidresearch See my post. BTW Casgevy actually achieved 8590% patients VOC free not advertised 95%"
X Link 2025-12-10T15:39Z 6835 followers, XXX engagements
"@avidresearch Only one is above XX% not many. For those approaching XX% they have high baseline HbF. The average HbF in BEAM-101 trial is 6.8%. So add 10-15% on top of that you have XX% for most as the figures showed. Besides patients have moderate anemia"
X Link 2025-12-10T15:56Z 6835 followers, XXX engagements